

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Singer Michael</u>  (Last) (First) (Middle) C/O CARTESIAN THERAPEUTICS, INC. 65 GROVE STREET  (Street) WATERTOWN MA 02472  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Cartesian Therapeutics, Inc. [ RNAC ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 11/13/2023	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
Rule 10b5-1(c) Transaction Indication <input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/13/2023		A		110,123	A	\$0 <sup>(1)</sup>	110,123	D	
Common Stock	11/13/2023		J		197,663	A	\$0 <sup>(1)</sup>	197,663	I	by trust <sup>(2)</sup>
Common Stock	11/13/2023		J		29,212	A	\$0 <sup>(1)</sup>	29,212	I	by trust <sup>(3)</sup>
Common Stock	11/13/2023		J		3,670	A	\$0 <sup>(1)</sup>	3,670	I	by trust <sup>(4)</sup>
Common Stock	11/13/2023		J		49,555	A	\$0 <sup>(1)</sup>	49,555	I	as custodian <sup>(5)</sup>
Common Stock	11/13/2023		J		49,555	A	\$0 <sup>(1)</sup>	49,555	I	as custodian <sup>(6)</sup>
Common Stock	11/13/2023		J		7,616	A	\$0 <sup>(1)</sup>	7,616	I	by spouse <sup>(7)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Series A Non-Voting Convertible Preferred Stock	(8)	11/13/2023		A		6,304,559		(8)	(8)	Common Stock	6,304,559	(1)	6,304,559	D	
Series A Non-Voting Convertible Preferred Stock	(8)	11/13/2023		J		11,316,263		(8)	(8)	Common Stock	11,316,263	(1)	11,316,263	I	by trust <sup>(2)</sup>
Series A Non-Voting Convertible Preferred Stock	(8)	11/13/2023		J		1,672,389		(8)	(8)	Common Stock	1,672,389	(1)	1,672,389	I	by trust <sup>(3)</sup>
Series A Non-Voting Convertible Preferred Stock	(8)	11/13/2023		J		210,152		(8)	(8)	Common Stock	210,152	(1)	210,152	I	by trust <sup>(4)</sup>
Series A Non-Voting Convertible Preferred Stock	(8)	11/13/2023		J		2,837,052		(8)	(8)	Common Stock	2,837,052	(1)	2,837,052	I	as custodian <sup>(5)</sup>
Series A Non-Voting Convertible Preferred Stock	(8)	11/13/2023		J		2,837,052		(8)	(8)	Common Stock	2,837,052	(1)	2,837,052	I	as custodian <sup>(6)</sup>
Series A Non-Voting Convertible Preferred Stock	(8)	11/13/2023		J		436,066		(8)	(8)	Common Stock	436,066	(1)	436,066	I	by spouse <sup>(7)</sup>

Explanation of Responses:

1. On November 13, 2023, Selecta Biosciences, Inc. (the "Company") acquired Cartesian Therapeutics, Inc. ("Cartesian") in accordance with the terms of an Agreement and Plan of Merger, dated November 13, 2023. These securities represent merger consideration payable as a result of the closing of the merger.

2. Shares are held in a trust for the benefit of the reporting person's spouse and children. The reporting person's spouse is a trustee of the trust.
3. Shares are held in a trust for which the reporting person is a beneficiary. The reporting person is a trustee of the trust.
4. Shares are held in a trust for which the reporting person is a beneficiary. The reporting person's spouse is a trustee of the trust.
5. The shares are held for LS, the child of the reporting person, through a custodial account established pursuant to the Uniform Transfer to Minors Act ("UTMA") for which the reporting person serves as custodian.
6. The shares are held for SS, the child of the reporting person, through a custodial account established pursuant to the UTMA for which the reporting person serves as custodian.
7. Shares are held by the reporting person's spouse.
8. Following the approval by the Stockholders of the conversion of the Series A Non-Voting Convertible Preferred Stock of the Company ("Series A Preferred Stock") into shares of common stock of the Company ("Common Stock"), each share of Series A Preferred Stock will be convertible into 1,000 shares of Common Stock, subject to certain limitations, including that a holder of Series A Preferred Stock is prohibited from converting shares of Series Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.9% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion.

/s/ Michael Singer

11/15/2023

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**